Incyte Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -2.59%204.730.0%$1953.60m
NVAXNovavax, Inc. -1.39%110.8278.2%$804.64m
AMGNAmgen, Inc. 1.95%235.361.4%$611.59m
BIIBBiogen, Inc. 1.11%239.301.8%$512.74m
GILDGilead Sciences, Inc. -0.15%71.771.0%$503.51m
BNTXBioNTech SE -3.44%196.000.0%$496.41m
ILMNIllumina, Inc. 1.41%405.143.3%$455.30m
REGNRegeneron Pharmaceuticals, Inc. -0.14%615.242.7%$435.16m
VRTXVertex Pharmaceuticals, Inc. 3.30%234.061.9%$373.05m
SNSSSunesis Pharmaceuticals, Inc. 2.26%3.170.7%$221.59m
INCYIncyte Corp. 1.67%74.882.4%$172.85m
EXASEXACT Sciences Corp. 4.02%78.4318.0%$156.45m
ARNAArena Pharmaceuticals, Inc. 0.20%92.6513.7%$151.27m
ALNYAlnylam Pharmaceuticals, Inc. 0.34%148.508.2%$147.48m
BMRNBioMarin Pharmaceutical, Inc. 2.34%90.224.2%$114.62m

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.